In English | En español
Questions About Cancer? 1-800-4-CANCER
  • Posted: 08/14/2012

Find News Releases

Search For:
Between these dates:

Page Options

  • Print This Page
  • Email This Document
NCI Cancer Center News

Penn Medicine study finds a class of diabetes drugs raises risk of bladder cancer

A popular class of diabetes drugs increases patients’ risk of bladder cancer, according to a new study published online this month in the Journal of the National Cancer Institute. Researchers from the Perelman School of Medicine at the University of Pennsylvania  found that patients taking thiazolidinedione (TZDs) drugs – which account for up to 20 percent of the drugs prescribed to diabetics in the United States -- are two to three times more likely to develop bladder cancer than those who took a sulfonylurea drug, another common class of medications for diabetes. The University of Pennsylvania is home to the Abramson Cancer Center.

Click here to read full press release.

###

NCI comprehensive cancer centers logoAmong the research institutions NCI funds across the United States, it currently designates 67 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.

 

This text may be reproduced or reused freely. Please credit the National Cancer Institute as the source. Any graphics may be owned by the artist or publisher who created them, and permission may be needed for their reuse.